Morgan Stanley Arbutus Biopharma Corp Put Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
182Shares Held
118MCall Options Held
1MPut Options Held
478K-
Whitefort Capital Management, LP New York, NY13.3MShares$59.9 Million14.31% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$51.9 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY10.4MShares$46.9 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$40.8 Million0.0% of portfolio
-
State Street Corp Boston, MA4.46MShares$20 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $673M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...